BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 17988723)

  • 1. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
    Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
    Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
    Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
    Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
    Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
    Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
    Connolly DC; Bao R; Nikitin AY; Stephens KC; Poole TW; Hua X; Harris SS; Vanderhyden BC; Hamilton TC
    Cancer Res; 2003 Mar; 63(6):1389-97. PubMed ID: 12649204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium.
    Wang J; Dicken C; Lustbader JW; Tortoriello DV
    Fertil Steril; 2009 Apr; 91(4):1195-203. PubMed ID: 18328480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
    Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
    Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice.
    El-Naggar SM; Malik MT; Martin A; Moore JP; Proctor M; Hamid T; Kakar SS
    J Endocrinol; 2007 Jul; 194(1):179-91. PubMed ID: 17592032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haymaker gene expression in malignant and normal gynecologic tissues.
    Borowsky ME; Das B; Axiotis CA; Malka ES; Abulafia O; Norin AJ
    J Histochem Cytochem; 2006 Jul; 54(7):753-61. PubMed ID: 16495475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
    Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
    Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines.
    Dowdy SC; Gostout BS; Shridhar V; Wu X; Smith DI; Podratz KC; Jiang SW
    Gynecol Oncol; 2005 Oct; 99(1):126-34. PubMed ID: 16023706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
    Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival.
    Yin X; Ouyang S; Xu W; Zhang X; Fok KL; Wong HY; Zhang J; Qiu X; Miao S; Chan HC; Wang L
    J Cell Sci; 2007 May; 120(Pt 9):1521-8. PubMed ID: 17452623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
    Wang P; Wu X; Chen W; Liu J; Wang X
    Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
    Andrews P; Zhao X; Allen J; Li F; Chang M
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer.
    Campos X; Muñoz Y; Selman A; Yazigi R; Moyano L; Weinstein-Oppenheimer C; Lara HE; Romero C
    Gynecol Oncol; 2007 Jan; 104(1):168-75. PubMed ID: 16935322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.
    Salceda S; Tang T; Kmet M; Munteanu A; Ghosh M; Macina R; Liu W; Pilkington G; Papkoff J
    Exp Cell Res; 2005 May; 306(1):128-41. PubMed ID: 15878339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
    Drapkin R; von Horsten HH; Lin Y; Mok SC; Crum CP; Welch WR; Hecht JL
    Cancer Res; 2005 Mar; 65(6):2162-9. PubMed ID: 15781627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy.
    Bagley RG; Rouleau C; Weber W; Mehraein K; Smale R; Curiel M; Callahan M; Roy A; Boutin P; St Martin T; Nacht M; Teicher BA
    Microvasc Res; 2011 Nov; 82(3):253-62. PubMed ID: 21958527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alteration of early growth response 1 expression in gastroenterological cancers and its biological significance].
    An J; Guo RF; Zhang L; Geng PL; Lü YY
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1384-9. PubMed ID: 18953875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
    Sakaguchi J; Kyo S; Kanaya T; Maida Y; Hashimoto M; Nakamura M; Yamada K; Inoue M
    Gynecol Oncol; 2005 Sep; 98(3):427-33. PubMed ID: 15993480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.